insights_auto
Why is BT3 down 6.90%?
Dive Deeperchevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
€0.78
arrow_downward
-6.90%(-0.058) 1D
Oct 2, 8:01:10 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BT3...
Open
€0.78
High
€0.78
Low
€0.78
Mkt. cap
235.30M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.69
52-wk low
€0.78
No. of employees
75
Open
€0.78
High
€0.78
Low
€0.78
Mkt. cap
235.30M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.69
52-wk low
€0.78
No. of employees
75
News stories
From web sources and news partners
24/7 Wall St.
·
17 minutes ago
S&P 500 at 7,718 Midday: Tech Takes the Lead With Nasdaq Up 1.1%
TradingView
·
1 hour ago
iShares S&P 500 BuyWrite ETF declares monthly distribution of $0.8844
The Detroit News
·
19 minutes ago
Nasdaq hits record high after softer jobs data cuts rate-hike bets
Quartz
·
3 hours ago
Dow futures jump after soft September jobs report, Oct 2026
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc